CNBC's Meg Tirrell reports the latest from the Vertex Pharmaceuticals earnings call. The "Fast Money" traders weigh in on trading the pharma and biotech space.
U.S. stock index futures pointed to a higher open on Tuesday as several large-cap companies reported better-than-expected quarterly results.
Samsung Bioepis has won regulatory approval for key biosimilar drug, the first time the company's product has been approved for U.S. use.
South Korea's Samsung Bioepis wins U.S. FDA nod for biosimilar of J&J's Remicade.
CNBC's Meg Tirrell discusses what healthcare investors should expect from the biotech sector. With the "Fast Money" traders.
Increases in the prices of drugs added $8.7 billion to 2016 net income for 28 companies analyzed, accounting for 100 percent of earnings growth last year.
Data covering the past five administrations show that Trump has enjoyed a relatively good, and surprising, market in his first 100 days.
Jim Cramer gave a dose of wisdom on a biotech company that is taking on the hemophilia space.
According to a filing from the U.S. Patent and Trademark Office, Forward Pharma has been interfering with Biogen.
Shares of Acorda were hit today after a District Court invalidated four patents for Ampyra, which represents 95 percent of the company's revenue. CNBC's Meg Tirrell reports.
CNBC's Meg Tirrell reports on the latest market action in the bio-tech sector.
The track record in drug development for Alzheimer's disease has been terrible: a success rate of less than 1 percent.
Jim Cramer identified one company with strong fundamentals that’s got the extra kicker of being an attractive takeover.
CNBC's Meg Tirrell reports on the victory for Biogen in its patent case over its Multiple Sclerosis drug.
Traders will likely watch international headlines Friday after the major events of the week have left stocks in a holding pattern.
U.S. stocks closed mostly lower Thursday as modest gains in financial stocks failed to offset declines in health care and utilities stocks.
Biogen shares are fully valued following the spinoff of its hemophilia business, Morgan Stanley argues.
Promising new research suggests that marijuana could be used to treat Alzheimer's, but there's a major roadblock: the federal government.
South Korea's Samsung Bioepis has won a high-stakes court case against U.S. drug firm AbbVie.
The hire signals Carl Icahn may be back, at a time when biotech valuations are 25 percent off their 2015 highs.